Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sheena McCormack

Showing results (101-110 of 117) with videos related to

Pageof 12
Sort By:
Frontiers in Immunology|March 10, 2017
A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization RegimesSarah Joseph, Killian Quinn, Aldona Greenwood, et al.
Human Gene Therapy|July 21, 2018
Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope VaccineHannah Mary Cheeseman, Suzanne Day, Leon Robert McFarlane, et al.
Journal of Virology|July 14, 2017
Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine RegimenAsli Bauer, Lilli Podola, Philipp Mann, et al.
Frontiers in Immunology|May 21, 2019
Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and SequenceYuka Nadai, Kathrin Held, Sarah Joseph, et al.
Plos One|April 21, 2017
Acceptability of an open-label wait-listed trial design: Experiences from the PROUD PrEP studyMitzy Gafos, Elizabeth Brodnicki, Monica Desai, et al.
Plos Pathogens|June 27, 2020
Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II TrialYves Lévy, Christine Lacabaratz, Kim Ellefsen-Lavoie, et al.
Plos One|November 30, 2018
Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial designEdna O Viegas, Arne Kroidl, Patricia J Munseri, et al.
Plos One|April 16, 2015
Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trialPatricia J Munseri, Arne Kroidl, Charlotta Nilsson, et al.
Lancet (London, England)|September 14, 2015
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trialSheena McCormack, David T Dunn, Monica Desai, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2024
Type 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Pooled Analysis From 72 Global StudiesRaphael J Landovitz, Li Tao, Juan Yang, et al.
Pageof 12

Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
Frontiers in Immunology|March 10, 2017
A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization RegimesSarah Joseph, Killian Quinn, Aldona Greenwood, et al.
Human Gene Therapy|July 21, 2018
Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope VaccineHannah Mary Cheeseman, Suzanne Day, Leon Robert McFarlane, et al.
Journal of Virology|July 14, 2017
Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine RegimenAsli Bauer, Lilli Podola, Philipp Mann, et al.
Frontiers in Immunology|May 21, 2019
Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and SequenceYuka Nadai, Kathrin Held, Sarah Joseph, et al.
Plos One|April 21, 2017
Acceptability of an open-label wait-listed trial design: Experiences from the PROUD PrEP studyMitzy Gafos, Elizabeth Brodnicki, Monica Desai, et al.
Plos Pathogens|June 27, 2020
Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II TrialYves Lévy, Christine Lacabaratz, Kim Ellefsen-Lavoie, et al.
Plos One|November 30, 2018
Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial designEdna O Viegas, Arne Kroidl, Patricia J Munseri, et al.
Plos One|April 16, 2015
Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trialPatricia J Munseri, Arne Kroidl, Charlotta Nilsson, et al.
Lancet (London, England)|September 14, 2015
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trialSheena McCormack, David T Dunn, Monica Desai, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2024
Type 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Pooled Analysis From 72 Global StudiesRaphael J Landovitz, Li Tao, Juan Yang, et al.
Pageof 12